NCT01942629

Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas

Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 300 (estimated)
• Sponsor: Rambam Health Care Campus · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The p63 gene is a recently discovered member of the p53 family located at chromosome 3q27Many studies have reported that overexpression of p63 can mimic p53 activities by binding DNA, activating transcription, and inducing apoptosis. Various studies proved p63 as a marker of basal cells in normal salivary glands, breast, prostate, respiratory and squamous epithelia, and of tumor cells from various malignancies. Still, p63 has been the subject of relatively few studies in lung adenocarcinoma, and breast carcinoma, and no study has described the correlation of p63 with pancreatic ductal adenocarcinoma. In the current study, we aim to evaluate the prognostic value of the expression of p63 in the lung adenocarcinoma, breast adenocarcinoma, and pancreatic ductal adenocarcinoma. We will achieve this aim by collecting clinical data retrospectively from the patients' medical records as well as assessing the histological sections and performing immunohistochemical staining for p63.

Conditions

• Lung Adenocarcinoma
• Breast Adenocarcinoma
• Pancreatic Ductal Adenocarcinoma

Interventions

Type	Name	Description
OTHER	their will be no intervention in any of the groups, the study is retrospective

Timeline

• Start date: 2013-10-01
• Primary completion: 2015-10-01
• Completion: 2015-12-01
• First posted: 2013-09-16
• Last updated: 2013-09-16